742 related articles for article (PubMed ID: 12221468)
1. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
2. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
Agrawal S; Kane JM; Guadagnolo BA; Kraybill WG; Ballo MT
Cancer; 2009 Dec; 115(24):5836-44. PubMed ID: 19701906
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
Kudriavtsev DV; Kudriavtseva GT; Mardynskiĭ IuS
Vopr Onkol; 2008; 54(2):170-7. PubMed ID: 18522165
[TBL] [Abstract][Full Text] [Related]
4. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
5. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
Fisher SR
Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
[TBL] [Abstract][Full Text] [Related]
6. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
7. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM
Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089
[TBL] [Abstract][Full Text] [Related]
8. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
Czarnetzki BM; Aragon V; Bröcker EB; Krieg V; Bünte H; Macher E
Dtsch Med Wochenschr; 1986 May; 111(19):732-6. PubMed ID: 3698850
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
11. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
14. [Preventive lymph node excision in the treatment concept of melanoma of the extremities].
Binder J; Henneking K
Zentralbl Chir; 1996; 121(6):474-7. PubMed ID: 8767334
[TBL] [Abstract][Full Text] [Related]
15. [Results of a randomized polychemotherapy study in malignant melanoma].
Fiedler H; Hetschko I; Wohlrab W; Wozniak KD; Lübbe D; Taube KM
Hautarzt; 1990 Jul; 41(7):369-74. PubMed ID: 1698185
[TBL] [Abstract][Full Text] [Related]
16. Management of malignant melanoma.
Kroon BB; Nieweg OE
Ann Chir Gynaecol; 2000; 89(3):242-50. PubMed ID: 11079795
[TBL] [Abstract][Full Text] [Related]
17. [Melanoma metastasis in the oropharynx].
Bootz F; Breuninger H; Lindstedt-Hilden M
HNO; 1994 May; 42(5):294-6. PubMed ID: 8050918
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
20. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
